电阻抗成像评估自主呼吸ARDS患者潮汐性复张/去复张的决定因素
本研究为既往研究的二次分析,纳入29例轻度镇静、压力支持通气(PSV)的ARDS患者,分别接受电阻抗成像(EIT)选择的呼气末正压(PEEPEIT)与低PEEP/FiO2表(PEEPTABLE)两种PEEP水平。中位PEEP在PEEPEIT为10.0 cmH2O、PEEPTABLE为8.0 cmH2O。总体潮汐性复张/去复张为14.3%,PEEPEIT时低于PEEPTABLE(11.3% vs 21.9%,P=0.008)。PEEPEIT减少复张/去复张与塌陷减少(rho=0.72)和摆动通气减少(rho=0.57)相关。多变量分析显示呼气末跨肺压、肺塌陷和非局灶性浸润是潮汐性复张/去复张的独立相关因素。
要点
- 在PSV自主呼吸的ARDS患者中,PEEPEIT(中位10.0 cmH2O)时潮汐性复张/去复张为11.3%,低于PEEPTABLE(中位8.0 cmH2O)的21.9%(P=0.008)。
- PEEPEIT降低潮汐性复张/去复张的程度与肺塌陷减少相关(rho=0.72,P<0.001),也与摆动通气减少相关(rho=0.57,P=0.002)。
- 混合效应模型显示,较低PEEP(P<0.001)、更负的呼气末跨肺压(P<0.001)、更大的肺塌陷(P<0.001)和更低的肺顺应性(P=0.002)时潮汐性复张/去复张更高。
- 更高的呼吸驱动(P=0.001)、呼吸努力(P=0.009)和动态驱动跨肺压(P=0.009)与更高的潮汐性复张/去复张相关。
- 非局灶性浸润患者的潮汐性复张/去复张更高(P=0.005);多变量分析中呼气末跨肺压、肺塌陷和非局灶性模式为独立相关因素。
适用人群与场景
- 轻度镇静、接受压力支持通气(PSV)的ARDS患者,来自既往研究;30例中1例因呼气末肺阻抗不稳定被排除,最终分析29例。
研究设计与关键结果
- 研究类型:既往研究的二次分析;样本量29例;人群为轻度镇静、PSV通气的ARDS患者;干预为EIT选择的PEEP(PEEPEIT)与低PEEP/FiO2表(PEEPTABLE)两种PEEP水平。
- 中位PEEP:PEEPEIT为10.0 cmH2O(IQR 8.0-12.0),PEEPTABLE为8.0 cmH2O(IQR 5.0-10.0)。
- 总体潮汐性复张/去复张为14.3%(IQR 9.0-33.0);PEEPEIT时11.3%(IQR 4.8-20.5)低于PEEPTABLE的21.9%(IQR 6.8-31.7),P=0.008。
- PEEPEIT减少复张/去复张与塌陷减少相关(rho=0.72,P<0.001),与摆动通气减少相关(rho=0.57,P=0.002)。
- 混合效应模型(合并两种随机PEEP数据):较低PEEP(P<0.001)、更负的呼气末跨肺压(P<0.001)、更大肺塌陷(P<0.001)、更低肺顺应性(P=0.002)时潮汐性复张/去复张更高。
- 更高的呼吸驱动(P=0.001)、呼吸努力(P=0.009)、动态驱动跨肺压(P=0.009)与更高的潮汐性复张/去复张相关;非局灶性浸润患者潮汐性复张/去复张更高(P=0.005)。
- 多变量分析:呼气末跨肺压、肺塌陷和非局灶性模式独立 associated with 潮汐性复张/去复张。
证据类型、等级与局限
- 局限:原文未报告局限性。
对床旁实践的改变
- 在PSV自主呼吸的ARDS患者中,EIT选择的PEEP(中位10.0 cmH2O)较低PEEP/FiO2表(中位8.0 cmH2O)降低潮汐性复张/去复张(11.3% vs 21.9%,P=0.008)。
- 更负的呼气末跨肺压、更高的肺塌陷和非局灶性浸润与更高的潮汐性复张/去复张独立相关;更高的呼吸驱动、呼吸努力和动态驱动跨肺压也与更高的潮汐性复张/去复张相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: Tidal recruitment/derecruitment (R/D) is a well-known mechanism of lung injury in acute respiratory distress syndrome (ARDS) patients, but its bedside identification is challenging during assisted ventilation.
OBJECTIVES: To investigate bedside determinants of tidal R/D assessed by electrical impedance tomography (EIT) in spontaneously breathing ARDS patients on pressure support ventilation (PSV).
METHODS: This is a secondary analysis of a previous study including lightly sedated ARDS patients ventilated on PSV at 2 positive end-expiratory pressure (PEEP) levels selected by EIT (PEEPEIT) and low PEEP/FiO2 table (PEEPTABLE). Detailed physiological assessment was performed, including respiratory mechanics, inspiratory drive and effort, regional mechanics, and tidal R/D measured by EIT.
MEASUREMENTS AND MAIN RESULTS: Of 30 original patients, 1 was excluded due to unstable end-expiratory lung impedance, leaving 29 patients for analysis. Median PEEP was 10.0 (IQR 8.0-12.0) cmH2O with PEEPEIT and 8.0 (IQR 5.0-10.0) cmH2O with PEEPTABLE. Overall, tidal R/D was 14.3% (IQR 9.0-33.0), but it was lower at PEEPEIT vs PEEPTABLE (11.3% [IQR 4.8-20.5] vs 21.9% [IQR 6.8-31.7]; P = .008). Recruitment/derecruitment reduction with PEEPEIT correlated with decreases in collapse (rho = 0.72; P < .001) and pendelluft (rho = 0.57; P = .002). Analyzing data from both randomized PEEPs together, mixed-effects models showed higher tidal R/D at lower PEEP (P < .001), more negative end-expiratory transpulmonary pressure (PLEnd-Exp) (P < .001), larger collapse (P < .001), and lower lung compliance (P = .002). Higher respiratory drive (P = .001), effort (P = .009), and dynamic driving transpulmonary pressure (P = .009) correlated with higher tidal R/D. Patients with nonfocal infiltrates presented higher tidal R/D (P = .005). At multivariable analysis, PLEnd-Exp, lung collapse, and nonfocal pattern were independently associated tidal R/D.
CONCLUSION: In spontaneously breathing ARDS patients on PSV, the main determinants of tidal R/D are more negative PLEnd-Exp, higher lung collapse, and nonfocal infiltrates.
参考来源
- Perez J, Leali M, Spinelli E, et al. Determinants of tidal recruitment/derecruitment assessed by electrical impedance tomography in spontaneously breathing acute respiratory distress syndrome patients. Am J Respir Crit Care Med. 2026. PMID: 42178817. doi:10.1093/ajrccm/aamag246
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。